+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Acute Kidney Injury Treatment Market (2021-2026) by Type, Treatment, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5392898
  • Report
  • April 2021
  • Region: Global
  • 187 Pages
  • Infogence Global Research

FEATURED COMPANIES

  • Abbott Laboratories
  • AM-Pharma
  • B. Braun Melsungen AG
  • F. Hoffmann-La Roche
  • LG Chem Ltd.
  • Randox Laboratories
The Global Acute Kidney Injury Treatment Market is estimated to be USD 1.6 Bn in 2021 and is expected to reach USD 2.52 Bn by 2026, growing at a CAGR of 9.5%.



Market Dynamics

The increasing prevalence of acute kidney injury is a major factor inclining the global acute kidney injury treatment market. According to the National Kidney Foundation, around 37 million people in the US are affected by kidney diseases. The increasing geriatric population, unhealthy diet, high consumption of alcohol has increased the risk of kidney injury. In addition, Acetaminophen and other drugs overdose, hepatitis and autoimmune diseases, metabolic diseases are also factors burgeoning market growth. Furthermore, increasing healthcare expenditure and government initiatives in improving the healthcare system is anticipated to increase the market revenue. However, the high cost of dialysis treatment and lack of patient compliance for a long-term treatment plan is hampering the market growth.

Major players are investing in developing novel treatments, which is expected to offer remunerative growth opportunities for the player operating in the market.

Market Segmentation

The Global Acute Kidney Injury Treatment Market is segmented further based on Type, Treatment, End User, and Geography.

By Type, the market is classified into prerenal, intrinsic renal, and postrenal. Amongst all, the prerenal segment is estimated to hold the highest market share during the forecast period.

By Treatment, the market is classified as dialysis and drug therapy. Amongst the two, the dialysis segment is estimated to hold the highest market share during the forecast period.

By End User, the market is classified as hospitals, diagnostic centers, specialty clinics, ambulatory surgical centers, and others. Amongst all, the hospitals segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Angion and Vifor pharma announce the completion of enrollment in phase 2 study of ANG-3777 for cardiac-surgery associated acute kidney injury. - 29th April 2021.
2. AM-pharma announces enrollment of the first patient in revival phase 3 pivotal trial in patients with sepsis-associated acute kidney injury. - 12th November 2020.

Company Profiles

Some of the companies covered in this report Quark Pharmaceuticals, Inc, Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, LG Chem Ltd., Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG, Alloksys Life Sciences BV, etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Acute Kidney Injury Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using the Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Acute Kidney Injury Treatment Market

What is the estimated value of the Global Acute Kidney Injury Treatment Market?

The Global Acute Kidney Injury Treatment Market was estimated to be valued at $1600.0 Million in 2021.

What is the growth rate of the Global Acute Kidney Injury Treatment Market?

The growth rate of the Global Acute Kidney Injury Treatment Market is 9.5%, with an estimated value of $2520.0 Million by 2026.

What is the forecasted size of the Global Acute Kidney Injury Treatment Market?

The Global Acute Kidney Injury Treatment Market is estimated to be worth $2520.0 Million by 2026.

Who are the key companies in the Global Acute Kidney Injury Treatment Market?

Key companies in the Global Acute Kidney Injury Treatment Market include Abbott Laboratories, Acon Laboratories, Alloksys Life Sciences B.V, AM, Pharma, Angion Biomedica Corp, Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG and Beckman Coulter, Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AM-Pharma
  • B. Braun Melsungen AG
  • F. Hoffmann-La Roche
  • LG Chem Ltd.
  • Randox Laboratories

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Prevalence of Acute Kidney Injury
4.1.2 Increasing Adoption of Biomarkers and Novel Treatment
4.1.3 Rising Geriatric Population
4.2 Restraints
4.2.1 High Cost of Treatments and Lack of Patient Compliance
4.2.2 Stringent Government Regulations
4.3 Opportunities
4.3.1 New Innovation in Medical Treatment
4.3.2 Growing Healthcare Sectors in Developing Countries
4.4 Challenges
4.4.1 Lack of Skilled Professional
4.4.2 Side Effects of Treatment
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Acute Kidney Injury Treatment Market, By Type
6.1 Introduction
6.2 Prerenal Acute Kidney Injury
6.3 Intrinsic Renal Acute Kidney Injury
6.4 Postrenal Acute Kidney Injury
7 Global Acute Kidney Injury Treatment Market, By Treatment
7.1 Introduction
7.2 Dialysis
7.2.1 Intermittent Hemodialysis
7.2.2 Continuous Renal Replacement Therapy (CRRT)
7.2.3 Sustained Low-Efficiency Dialysis (SLED)
7.3 Drug Therapy
7.3.1 Antibiotics
7.3.2 Diuretics
7.3.3 Immunosuppressive Agents
8 Global Acute Kidney Injury Treatment Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Diagnostic Centers
8.4 Specialty Clinics
8.5 Ambulatory Surgical Centers
8.6 Others
9 Global Acute Kidney Injury Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.3.3 Chile
9.3.4 Colombia
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Spain
9.4.6 Netherlands
9.4.7 Sweden
9.4.8 Russia
9.4.9 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Indonesia
9.5.5 Malaysia
9.5.6 South Korea
9.5.7 Australia
9.5.8 Sri Lanka
9.5.9 Thailand
9.5.10 Rest of APAC
9.6 Middle-East and Africa
9.6.1 Qatar
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Strategic Initiatives
10.3.1 M&A and Investments
10.3.2 Partnerships and Collaborations
10.3.3 Product Developments and Improvements
11 Company Profiles
11.1 Abbott Laboratories
11.2 Acon Laboratories
11.3 Alloksys Life Sciences B.V
11.4 AM-Pharma
11.5 Angion Biomedica Corp
11.6 Asahi Kasei Medical Co., Ltd
11.7 B. Braun Melsungen AG
11.8 Baxter International, Inc.
11.9 Beckman Coulter, Inc.
11.10 F. Hoffmann-La Roche
11.11 Fresenius Medical Care AG & Co. KGaA
11.12 Ischemix, Inc.
11.13 LG Chem Ltd.
11.14 Quark Pharmaceuticals, Inc
11.15 Quest Diagnostics
11.16 Randox Laboratories
11.17 Siemens Healthineers
11.18 Silver Creek Pharmaceuticals, Inc.
11.19 Stealth Bio Therapeutics, Inc.
11.20 Sysmex Corporation
12 Appendix
12.1 Questionnaire
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Acon Laboratories
  • Alloksys Life Sciences B.V
  • AM-Pharma
  • Angion Biomedica Corp
  • Asahi Kasei Medical Co., Ltd
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche
  • Fresenius Medical Care AG & Co. KGaA
  • Ischemix, Inc.
  • LG Chem Ltd.
  • Quark Pharmaceuticals, Inc
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthineers
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth Bio Therapeutics, Inc.
  • Sysmex Corporation
Note: Product cover images may vary from those shown